Inhibition of Bradykinin Receptor B1 Protects Mice from Focal Brain Injury by Reducing Blood–Brain Barrier Leakage and Inflammation

Inhibition of bradykinin B2 receptors before, not after onset of experimental subarachnoid hemorrhage prevents brain edema formation and improves functional outcome

(2009) Serge C. Thal et al.   CRITICAL CARE MEDICINE

The Role of Bradykinin B1 and B2 Receptors for Secondary Brain Damage after Traumatic Brain Injury in Mice

(2009) Raimund Trabold et al.   JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM

Combination Therapies for Traumatic Brain Injury: Prospective Considerations

(2009) Susan Margulies et al.   JOURNAL OF NEUROTRAUMA

Pathophysiology of traumatic brain injury

(2009) Mark W. Greve et al.   MOUNT SINAI JOURNAL OF MEDICINE

Retracted Article: Differential effects of endothelin receptor A and B antagonism on cerebral hypoperfusion following traumatic brain injury

(2009) Christian W Kreipke et al.   NEUROLOGICAL RESEARCH

Anatibant®, a selective non-peptide bradykinin B2 receptor antagonist, reduces intracranial hypertension and histopathological damage after experimental traumatic brain injury

(2009) Klaus Zweckberger et al.   NEUROSCIENCE LETTERS

Unknown

(2008) Kathryn Beauchamp et al.   MOLECULAR MEDICINE

Blockade of Bradykinin Receptor B1 but Not Bradykinin Receptor B2 Provides Protection From Cerebral Infarction and Brain Edema

(2008) Madeleine Austinat et al.   STROKE

The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?

(2007) N S Kirkby et al.   BRITISH JOURNAL OF PHARMACOLOGY